Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 28
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/6/2009
 
First Published:
4/23/2004
1.
Phase III Randomized Study of Exemestane in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Active
35 and over
Other, Pharmaceutical / Industry
CAN-NCIC-MAP3
PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3
Last Modified:
7/23/2008
 
First Published:
8/3/2007
2.
Phase III Randomized Study of the Effects of Dietary Soy on Estrogens in Breast Fluid, Serum, and Urine Samples From Healthy Women
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Active
30 to 45
NCI
UHM-CHS-4116
CHS 14116, NCT00513916
First Published:
10/31/2007
3.
Phase III Randomized Study of Continuous Letrozole Versus Intermittent Letrozole in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive, Early-Stage Breast Cancer After Completion of 4 to 6 Years of Prior Adjuvant Endocrine Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Active
Postmenopausal
Other
IBCSG-35-07
IBCSG-35-07, BIG-1-07-SOLE, EUDRACT-2007-001370-88, NCT00553410
Last Modified:
8/27/2008
 
First Published:
5/5/2008
4.
Phase III Randomized Study of Letrozole in Preventing Breast Cancer in Postmenopausal Women With the BRCA1/BRCA2 Mutation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Active
40 to 69
Other, Pharmaceutical / Industry
FNCLCC-ONCO-03/0701
FNCLCC-ONCO 03/0701 - LIBER, EU-20806, NOVARTIS-FNCLCC-ONCO 03/0701, NCT00673335
First Published:
3/18/2008
5.
Randomized Study of Prophylactic Cranial Radiotherapy in Women With Metastatic or Locally Advanced Breast Cancer Previously Treated With Trastuzumab (Herceptin®) and Taxane Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention, Treatment
Active
18 and over
Other
ACCOG-HER-PCI
ACCOG-HER-PCI, ISRCTN64624715, EU-20822, NCT00639366
6.
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Active
30 to 75
Other
GD-10-08
NCT00808522
Last Modified:
8/27/2008
 
First Published:
3/24/2004
7.
Phase II Pilot Chemoprevention Study of Deslorelin in Combination With Low-Dose Add-Back Estradiol and Testosterone in Premenopausal Women With or Without a BRCA Gene Mutation Who Are at High Risk for Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Active
21 to 48
NCI
CHNMC-IRB-02164
NCT00080756
Last Modified:
1/5/2009
 
First Published:
5/28/2004
8.
Phase II Study of Exemestane in Postmenopausal Women at High Risk for Invasive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Active
Postmenopausal
NCI
GUMC-2007-313
NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313
Last Modified:
10/11/2007
 
First Published:
8/24/2004
9.
Phase II Randomized Pilot Study of Letrozole in Postmenopausal Women at Increased Risk For Breast Cancer Based on Elevated Estradiol Levels
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Active
35 and over
NCI
DFCI-00024
UCLA-0210012-02, NCT00090857
10.
Soy Protein and Breast Cancer Risk Reduction
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Active
30 to 40
Other
02-422
Army's HSRRB log no. A-10926, UTMB GCRC 533, DAMD17-01-1-0417, NIH NCRR GCRC M01 RR00073, NCT00204477
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute